Phenotypes and enviromental factors: Their influence in PCOS

Current Pharmaceutical Design

Volumn 18, Issue 3, 2012, Pages 270-282

  Diamanti Kandarakis, Evanthia ^a   Christakou, Charikleia ^a   Marinakis, Evangelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

AGEs; Diet; Endocrine disruptors; Environment; PCOS; Phenotypes

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ADVANCED GLYCATION END PRODUCT; ANDROGEN; CLOMIFENE CITRATE; ENDOCRINE DISRUPTOR; METFORMIN;

ANOVULATION; ARTICLE; DIET; DISEASES; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENETIC HETEROGENEITY; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIFE CYCLE; LIFESTYLE; METABOLIC DISORDER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; OVERNUTRITION; OVULATION INDUCTION; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

DIET; DISEASE SUSCEPTIBILITY; ENDOCRINE DISRUPTORS; ENVIRONMENTAL EXPOSURE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OBESITY; PHENOLS; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

EID: 84856435984     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799040457     Document Type: Article

References (179)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84(11): 4006-11.
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications 1990; pp. 377-84
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18(6): 774-800. Review.
4. Diamanti-Kandarakis E & Christakou C. In Farid NR & Diamanti-Kandarakis E, Ed. Diagnosis and Management of Polycystic Ovary Syndrome. Springer 2009a; pp.35-52
5. Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006a; 5(1): 17-34. Review.
6. Muniyappa R, Montagnani M, Kon Koh K, Quon M. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-91.
7. Poretsky L, Cataldo N, Rosenwaks Z, Guidice L. Insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582
8. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996; 81(1): 302-9.
9. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004; 10(2): 107-17. Review.
10. Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000; 85(11): 4047-52.
11. Blank SK, McCartney CR, Chhabra S, et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation. J Clin Endocrinol Metab. 2009; 94(7): 2360-6.
12. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 1010: 2622-2629.
13. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Frauser BC. Anti-Mullerian hormone serum concentrations in normovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318-323.
14. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91(3): 941-5.
15. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. AntiMüllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009; 296: E238-E24.
16. Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92(1): 240-5.
17. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010; 139(5): 825-33.
18. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88(12): 5957-62.
19. Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007; 18(7): 266-72. Review.
20. Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health (Lond Engl) 2008; 4(6): 583-94. Review.
21. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007; 8(2): 127-41. Review.
22. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE: Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17: 2573-9.
23. Kragie L. Aromatase in primate pregnancy: a review. Endocr Res 2002; 28: 121-128.
24. Hickey M, Slooda DM, Atkinson HC, et al. The Relationship between Maternal and Umbilical Cord Androgen Levels and Polycystic Ovary Syndrome in Adolescence: A Prospective Cohort StudyJ Clin Endocrinol Metab 2009(10); 3714-20.
25. Anderson H, Fogel N, Grebe SK, Singh RJ, Taylor RL, Dunaif A. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab. 2010; 95(5): 2180-6.
26. de Zegher F, Lopez-Bermejo A, Ibanez L. Adipose tissue expandability and the early origins of polycystic ovarian syndrome. Trends Endocrinol Metab 2009a; 20(9): 418-23.
27. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008; 6: e237.
28. Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83: 3558-3562
29. Ibáñez L, Díaz R, López-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009; 10(1): 63-76. Review.
30. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13 (6): 946-57.
31. Cortón M, Botella-Carretero JI, Benguría A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92(1): 328-37.
32. Cortón M, Botella-Carretero JI, López JA, et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum Reprod 2008; 23(3): 651-61.
33. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288(5): E1047-54.
34. Corbould A, Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism 2007; 56(5): 716-22.
35. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80,123-126
36. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91(1): 336-40
37. Victor VM, Rocha M, Bañuls C, et al. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2009; 94(9): 3505-12.
38. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998; 95(25): 14956-60.
39. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005; 26(2): 251-82
40. Yildiz BO, Goodarzi MO, Guo X, Rotter JI, Azziz R. Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. Fertil Steril 2006; 86: 1688-1693
41. Jones MR, Mathur R, Cui J, Guo X, Azziz R, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab 2009; 94(12): 5034-8.
42. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007; 92(11): 4191-98.
43. Ewens K, Stewart DR, Ankener W, et al. Family-Based Analysis of Candidate Genes for Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab 2010; 95(5): 2306-2315.
44. Segars JH and DeCherney AH. Is there a genetic basis for Polycystic Ovary, Syndrome? J Clin Endocrinol Metab 2010, 95(5): 2058-2060
45. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
46. Azziz R: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91: 781-5.
47. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988; 1: 870-872.
48. Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2004; 89(9): 4343-50.
49. Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009; 94: 1579-1586.
50. Balen AH, Laven J, Tan SL and Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions Hum Reprod Update 2003; 9: 505-514
51. Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005; 90: 2571-9.
52. Murphy MK, Hall JE, Adams JM, Lee H, Welt CK. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 3878-84.
53. Azziz R, Carmina E, Dewailly D, et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91(2): 456-88.
54. Ibáñez L, López-Bermejo A, Callejo J, et al. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth. J Clin Endocrinol Metab 2008; 93(1): 196-9.
55. Melo A, Vieira C, Barbieri M, et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum. Reprod 2010; 25(8): 2124-2131.
56. Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997; 350(9085): 1131-5.
57. de Zegher F, Ibáñez L. Early Origins of polycystic ovary syndrome: hypotheses may change without notice. J Clin Endocrinol Metab. 2009; 94(10): 3682-5.
58. Verkauskiene R, Beltrand J, Claris O, et al. Impact of fetal growth restriction on body composition and hormonal status at birth in infants of small and appropriate weight for gestational age. Eur J Endocrinol 2007; 157(5): 605-12.
59. Dulloo AG. Thrifty energy metabolism in catch-up growth trajectories to insulin and leptin resistance. Best Pract Res Clin Endocrinol Metab 2008; 22(1): 155-71. Review
60. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284.
61. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn BA, Cedars MI. Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab 2011; 96(1): E114-8.
62. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 91: 4842-8.
63. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007 a; 67 (5): 735-42.
64. Moran L and Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome Hum. Reprod. Update 2009; 15(4): 477-488.
65. Goverde AJ, van Koert AJB, Eijkemans MJ, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum. Reprod 2009; 24(3): 710-717.
66. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG 2009; 116(12): 1633-9.
67. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049.
68. Rizzo M, Berneis K, Hersberger M, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24(9): 2286-92.
69. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13: 251-7.
70. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 162-8.
71. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492-7.
72. Vigil P, Contreras P, Alvarado JL, Godoy A, Salgado AM, Cortes ME. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum Reprod 2007; 22: 2974-80.
73. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 113(10): 1148-59. Review.
74. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92(6): 1966-82.
75. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90: 6364-9.
76. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006; 113: 1203-9.
77. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561.
78. Harman-Boehm I, Blüher M, Redel H,. et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the co-morbidities of obesity. J. Clin. Endocrinol. Metab 2007; 92, 2240-2247.
79. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006; 444, 860-867.
80. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest 2003; 112: 1796-1808.
81. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest 2003; 112: 1821-1830.
82. Rudich A, Kanety H and Bashan N. Adipose stress-sensing kinases: linking obesity to malfunction Trends Endocrinol Metab 2007; 18(8): 291-299
83. Gosman GG, Katcher HI, Legro RS. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update. 2006; 12(5): 585-601.
84. Brewer C and Balen A. The adverse effects of obesity on conception and implantation Reproduction 2010; 140: 347-364.
85. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2760-6.
86. Stewart PM, Shackleton CH, Beastall GH, Edwards CR.5 alphareductase activity in polycystic ovary syndrome. Lancet 1990; 335: 431-3.
87. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183: 331-42.
88. Garnett SP, Cowell CT, Baur LA, et al. Abdominal fat and birth size in healthy prepubertal children. Int J Obes Relat Metab Disord 2001; 25(11): 1667-73.
89. Ibáñez L, Suárez L, Lopez-Bermejo A, Díaz M, Valls C, de Zegher F. Early development of visceral fat excess after spontaneous catchup growth in children with low birth weight. J Clin Endocrinol Metab 2008; 93(3): 925-8.
90. Ong KK, Potau N, Petry CJ, et al. Opposing Influences of Prenatal and Postnatal Weight Gain on Adrenarche in Normal Boys and Girls. J Clin Endocrinol Metab 2004; 89: 2647-2651.
91. Frisch RE. Body fat, menarche, fitness and fertility. Hum Reprod 1987; 2: 521-533.
92. Parker LN. Adrenarche. Endocrinol Metab Clin North Am 1991; 20(1): 71-83. Review.
93. Cooper C, Kuh D, Egger P, Wadsworth M, Barker D. Childhood growth and age at menarche. Br J Obstet Gynaecol 1996; 103: 814-817.
94. Sloboda DM, Hart R, Doherty DA, Pennell CE, Hickey M. Age at Menarche: Influences of Prenatal and Postnatal Growth. J Clin Endocrinol Metab 2007; 92(1): 46-50.
95. Catalano PM. Increasing Maternal Obesity and Weight Gain During Pregnancy: The Obstetric Problems of Plentitude. Obstet Gynecol 2007; 110: 743-744.
96. Howie GJ, Sloboda DM, Kamal T, Vickers MH. Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. J Physiol 2009; 587(Pt 4): 905-15.
97. Kristensen J, Vestergaard M, Wisborg K, Kesmodel U, Secher NJ. Pre-pregnancy weight and the risk of stillbirth and neonatal death. BJOG 2005; 112(4): 403-8.
98. Sloboda DM, Howie GJ, Pleasants A, Gluckman PD, Vickers MH. Pre-and postnatal nutritional histories influence reproductive maturation and ovarian function in the rat. PLoS One 2009; 4(8): e6744.
99. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-46.
100. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-91.
101. Vlassara H. Advanced glycation in health and disease: role of the modern environment Ann NY Acad Sci 2005; 1043: 452-60.
102. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62(1): 37-43.
103. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69(4): 634-41
104. Diamanti-Kandarakis E, Piouka A, Livadas S, et al. Antimullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160(5): 847-53.
105. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99(24): 15596-601.
106. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators. Inflamm 2010; 792393.
107. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006; 21(6): 1426-31.
108. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006; 36(10): 691
109. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86(10): 4666
110. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 749-56.
111. Christakou C, et al. Strong and positive association of Endothelin-1 with AGEs in PCOS: A causal relationship or a bystander? Under revision: Hormones 2011.
112. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al: Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007; 127: 581-9.
113. Lischinsky A, Armstrong DT Granulosa cell stimulation of thecal androgen synthesis. Can J Physiol Pharmacol 1983; 61: 472-477.
114. Wachs DS, Coffler MS, Malcom PJ, Shimasaki S, Chang RJ. Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93(5): 1827-33.
115. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med 2007; 85(12): 1413-20.
116. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009; 24: 2917-2923
117. Tatone C, Amicarelli F, Carbone MC, et al. Cellular and molecular aspects of ovarian follicle ageing. Hum Reprod Update 2008; 14(2): 131-42. Review.
118. Tatone C, Carbone MC, Campanella G, et al. Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductivelyaged mice. J Biol Regul Homeost Agents 2010; 24(1): 63-72.
119. Jinno M, Takeuchi M, Watanabe A, et al. Advanced glycation endproducts accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod 2011; 26(3): 604-10.
120. Mericq V, Piccardo C, Cai W, et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 2010; 33(10): 2232-7.
121. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30(4): 293-342. Review.
122. Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y and Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 2002; 17(11): 2839-2841.
123. Takeuchi T, Tsutsumi O, Ikezuki Y, et al. Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocr J 2006; 53: 485-91.
124. Zhou W, Liu J, Liao L, Han S, Liu J. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol. 2008; 283(1-2): 12-8.
125. Kato H, Ota T, Furuhashi T, Ohta Y, Iguchi T. Changes in reproductive organs of female rats treated with bisphenol A during the neonatal period. Reproductive Toxicology 2003; 17: 283-288.
126. Adewale HB, Jefferson WN, Newbold RR, Patisaul HB. Neonatal bisphenol-a exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropinreleasing hormone neurons. Biol Reprod. 2009; 81(4): 690-9.
127. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol. 2000; 163(1-2): 49-52.
128. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c17 alpha as the cause of polycystic ovarian syndrome. Fertil. Steril 1990; 53: 85-91.
129. Mlynarcíková A, Kolena J, Fickov́a M, Scsukov S. Alterations in steroid hormone production by porcine ovarian granulose cells caused by bisphenol A and bisphenol A dimethacrylate. Mol Cell Endocrinol. 2005; 244(1-2): 57-62.
130. Newbold RR, Jefferson WN, Padilla-Banks E. Long-term Adverse Effects of Neonatal Exposure to Bisphenol A on the Murine Female Reproductive Tract. Reprod Toxicol 2007; 24(2): 253-258.
131. Newbold RR, Jefferson WN, Padilla-Banks E. Prenatal Exposure to Bisphenol A at Environmentally Relevant Doses Adversely Affects the Murine Female Reproductive Tract Later in Life. Environ Health Perspect 2009; 117: 879-885.
132. Lang IA, Galloway TS, Scarlett A et al. Association of Urinary Bisphenol A Concentration With Medical Disorders and Laboratory Abnormalities in Adults. JAMA 2008; 300(11): 1303-1310.
133. Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. Association of Urinary Bisphenol A Concentration with Heart Disease: Evidence from NHANES 2003/06. PLoS One. 2010; 5(1): e8673.
134. Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben-Jonathan N. Bisphenol A at Environmentally Relevant Doses Inhibits Adiponectin Release from Human Adipose Tissue Explants and Adipocytes. Environ Health Perspect 2008; 116: 1642-1647.
135. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring). 2006; 14(5): 242-249.
136. Ben-Jonathan N, Hugo ER, and Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. Mol Cell Endocrinol 2009; 304(1-2): 49-54.
137. Masuno H, Kidani T, Sekiya K, et al. Bisphenol A in combination with insulin can accelerate the conversion of 3T3-L1 fibroblasts to adipocytes. J Lipid Res. 2002; 43(5): 676-84.
138. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci. 2005; 84(2): 319-27.
139. Wada K, Sakamoto H, Nishikawa K, et al. Lifestyle-related diseases of the digestive system: endocrine disruptors stimulate lipid accumulation in target cells related to metabolic syndrome. J Pharmacol Sci. 2007; 105(2): 133-7.
140. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The Estrogenic Effect of Bisphenol-A Disrupts Pancreatic β-Cell Function In Vivo and Induces Insulin Resistance. Environ Health Perspect 2006; 114(1): 106-12.
141. Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low Doses of Bisphenol A and Diethylstilbestrol Impair Ca2+ Signals in Pancreatic-Cells through a Nonclassical Membrane Estrogen Receptor within Intact Islets of Langerhans. Environ Health Perspect 2005; 113(8): 969-77.
142. Sakurai K, Kawazuma M, Adachi T, et al. Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. Br J Pharmacol. 2004; 141(2): 209-14.
143. Alonso-Magdalena P, Vieira E, Soriano S, et al. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect. 2010; 118(9): 1243-50.
144. Fernández M, Bianchi M, Lux-Lantos V, Libertun C. Neonatal Exposure to Bisphenol A Alters Reproductive Parameters and Gonadotropin Releasing Hormone Signaling in Female Rats. Environ Health Perspect 2009; 117: 757-762.
145. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J. 2004; 51(2): 165-9.
146. Takeuchi T, Tsutsumi. Serum Bisphenol A Concentrations Showed Gender Differences, Possibly Linked to Androgen Levels. Bioch Bioph Res Com 2002; 291: 76-78.
147. Déchaud H, Ravard C, Claustrat F, de la Perrière AB, Pugeat M. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1999; 64: 328-34.
148. Hanioka N, Jinno H, Nishimura T, Ando M. Suppression of malespecific cytochrome P450 isoforms by bisphenol A in rat liver. Arch Toxicol 1998; 72: 387-94.
149. Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine Disruptors and Polycystic Ovary Syndrome (PCOS): Elevated Serum Levels of Bisphenol A in Women with PCOS. J Clin Endocrinol Metab 2011; 96(3): E480-4.
150. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 2586-2593.
151. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-1474.
152. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105-111.
153. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93: 4299-4306.
154. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010b; 162(2): 193-212.
155. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril 2011; 95(2): 727-30.
156. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr. 2010; 156(1): 98-102. e1.
157. Romualdi D, Costantini B, Selvaggi L, et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008; 23: 2127-33.
158. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normalweight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90: 6072-76.
159. Topcu S, Tok D, Caliskan M, et al. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol (Oxf) 2006; 65: 75-80.
160. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-23.
161. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075-79.
162. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358: 47-54.
163. Rice S, Pellatt LJ, Bryan SJ, Whitehead SA, Mason HD. Action of metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells. J Clin Endocrinol Metab 2011; 96(3): E427-35.
164. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79: 956-62.
165. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56(1): 129-34.
166. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30: 1-50.
167. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005; 90: 729-733.
168. Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 2008; 89: 899-906.
169. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66: 103-109.
170. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004; 82: 1193-97.
171. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen activated protein kinase pathway. Fertil Steril 2006; 86: 1053-58.
172. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab 2010; 95(12): 5390-94.
173. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006; 85(4): 996-1001.
174. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective randomized cross-over trial. J Clin Endocrinol Metab 2007; 92(2): 456-61.
175. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94(12): 4938-45.
176. Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164(1): 53-60
177. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77: 91-97
178. Burgers JA, Fong SL, Louwers YV, et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?J Clin Endocrinol Metab 2010; 95(12): E485-9.
179. Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The Metabolic Status Modulates the Effect of Metformin on the Antimüllerian Hormone-Androgens-Insulin Interplay in Obese Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2011 Feb 9. [Epub ahead of print].